GGrantIndex
Sort

64,565 grants matching drug discovery

Vaccines and Therapeutics for Anthrax

$1,066,759
Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

UIC: In vitro In vivo Mtb Pharmacology

$1,066,689
Scott G. Franzblau · Global Alliance For Tb Drug Development · U19 · FY2021 · AI

Red Cell Biology

$1,066,618
David M. Bodine · National Human Genome Research Institute · ZIA · FY2022 · HG

ADDITIVE MANUFACTURING OF PDMS MICROFLUIDICS

$1,066,595
Jeffrey Schultz · Phase, Inc. · R44 · FY2023 · TR

Center of Excellence for High Throughput Proteogenomic Characterization

$1,066,337
Steven A. Carr · Broad Institute, Inc. · U24 · FY2023 · CA

Targeting Pediatric Cancer Vulnerabilities

$1,066,178
Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2023 · CA

RADIANT

$1,066,134
Ashok Balasubramanyam · Baylor College Of Medicine · U54 · FY2024 · DK

UMGCC Paul Calabresi Clinical Oncology Training Program

$1,065,746
Edward A Sausville · University Of Maryland Baltimore · K12 · FY2012 · CA

Integrating targeted and immunotherapy to treat genetically heterogeneous cancers

$1,065,613
William A Weiss · University Of California, San Francisco · U01 · FY2017 · CA

Parent Project - Main Theme (MAIN)

$1,065,585
Mark J Ratain · University Of Chicago · U01 · FY2011 · GM

Mixed Opioid Agonists / Cholecystokinin Antagonists for Treatment of Pain

$1,065,579
Edward Roberts · Scripps Research Institute, The · U01 · FY2007 · NS

Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.

$1,065,515
Paul J Higgins · Paratek Pharmaceuticals · U01 · FY2010 · NS

Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.

$1,065,515
Paul Higgins · Paratek Pharmaceuticals · U01 · FY2010 · NS

Targeting Pediatric Cancer Vulnerabilities

$1,065,492
Kimberly Stegmaier · Dana-Farber Cancer Inst · R35 · FY2025 · CA

A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION

$1,065,481
Steven Carl George · University Of California At Davis · UH3 · FY2021 · HL

Center for Genomics and Society

$1,065,387
Gail E Henderson · Univ Of North Carolina Chapel Hill · P50 · FY2008 · HG

RNAi Screening in Hematopoietic Cells

$1,065,285
Iain Fraser · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Use of systems pharmacology to prevent rod and cone photoreceptor degeneration

$1,065,041
Krzysztof Palczewski · University Of California-Irvine · R24 · FY2018 · EY

AdaptiSPECT-C: A Next-Generation, Adaptive Brain-Imaging SPECT System for Drug Discovery and Clinical Imaging

$1,064,648
Michael A King · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · EB

NIDA Center of Excellence OF Computational Drug Abuse Research (CDAR)

$1,064,603
Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · P30 · FY2015 · DA

COBRE Transitional Center in Neuroscience

$1,064,491
George A Spirou · West Virginia University · P30 · FY2014 · GM

Identification of novel MDR antimicrobials from symbioses between terrestrial and marine invertebrates and rare microbial taxa

$1,064,370
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2019 · AI

Regulation of Osteoblast Differentiation by Delta FosB

$1,063,933
Roland E Baron · Harvard Medical School · R01 · FY2009 · AR

Center for Targeted Therapeutics 2

$1,063,913
Hippokratis Kiaris · University Of South Carolina At Columbia · P20 · FY2023 · GM

SRC ON PRIMARY AND METASTATIC TUMORS OF THE CNS

$1,063,812
Duke University · P50 · FY2000 · NS